本报讯（记者 马晓冬）昨日，京津冀三地自贸试验区共同发布第一批全产业链协同发展机会清单（以 下简称清单），聚焦生物医药、数字经济、现代物流等重点领域，梳理41家重点企业在产供链体系建设 和区域协作方面的供给能力和合作需求，搭建精准对接平台。 在生物医药产业链方面，清单整合了医药研发、生产、流通、临床应用等领域企业的信息，涉及人工智 能与药物研发、基因编辑与细胞治疗、临床试验与转化服务、进出口与通关服务等方面的合作机会。在 数字经济产业链方面，清单整合算力、数据、安全、信创等领域企业的信息，内容包含资源共享、数据 跨境流通、网络安全共建、产业数字化赋能等。在现代物流产业链方面，清单涵盖国际物流、运输服 务、供应链金融、冷链仓储等行业领域的信息，例如多式联运、冷链物流、保税仓储、物流信息平台共 建等。 转自：天津日报 据了解，京津冀三地自贸试验区将围绕全产业链协同创新，结合企业实际需求持续搭建对接交流平台， 结合北京科技创新优势、天津先进制造研发优势和河北环京津地缘优势，推动技术联合攻关、科技资源 开放共享、应用场景联建联用，合力打造区域协同开放典范、全产业链创新高地，持续提升京津冀自贸 试验区全产业链创新发展水 ...

Core Insights - Liaoning Province has recognized a total of 777 provincial-level agricultural industrialization leading enterprises, including 84 at the national level [1] - The 20th batch of provincial-level key leading enterprises includes 71 companies, such as Shenyang Haoming Poultry Co., Ltd. and Shenyang Yunkeng Feed Co., Ltd. [1] Summary by Categories Enterprise Recognition - The provincial agricultural and rural affairs department, along with other governmental bodies, has released the latest list of key leading enterprises [1] - The recognized enterprises must meet specific criteria, including total assets exceeding 30 million yuan, fixed assets over 20 million yuan, and annual sales revenue above 50 million yuan [1] Monitoring and Support - The recognized enterprises will benefit from supportive policies until the end of 2027 [1] - A dynamic monitoring mechanism is in place, with three enterprises qualifying for the 2024 provincial-level key leading enterprise list, while ten others were disqualified [1] Industry Impact - Leading enterprises are considered the main force in transforming Liaoning into a major food industrial province and serve as a model for the integration of primary, secondary, and tertiary industries [1]

Core Viewpoint - The logistics industry in China shows continued expansion in demand and positive expectations, with key indices remaining in a prosperous range [1]. Group 1: Logistics Industry Performance - The logistics industry prosperity index for November is 50.9%, reflecting a month-on-month increase of 0.2 percentage points [2]. - The business volume index for the central and western regions is 51% and 51.2%, respectively, surpassing the national average, while the eastern region's index is 50.5%, with a month-on-month increase of 0.1 percentage points [2]. - The logistics demand for industrial products has rebounded compared to the previous month, while energy logistics demand continues to decline [6]. Group 2: Investment and Future Expectations - The fixed asset investment index for the logistics industry in November is 55.4%, indicating a high level of prosperity [9]. - Research indicates that trade logistics companies have high investment demand in areas such as equipment sharing and adaptation of upstream and downstream facilities [9]. - The business activity expectation index for November is 54.9%, remaining in a high prosperity range, with multi-modal transport, air transport, and postal express industries maintaining high levels of business activity expectations [9].

Core Insights - The research team from Shandong Province conducted an investigation into the seafood market in Qingdao, focusing on production, sales, and price trends following the end of the fishing moratorium [1][2] - The team visited key seafood distribution centers and engaged with local vendors to gather insights on supply channels, cost fluctuations, and sales challenges [1] - The meeting included representatives from various seafood farming, processing, and distribution companies, discussing resource status, production costs, and market expectations [1] Group 1 - The investigation revealed a significant recovery in the resource levels of major economic fish species in the Yellow Sea after the fishing moratorium [1] - The overall stability in the aquaculture sector was noted, alongside accelerated development in deep-sea farming [1] - Processing companies are facing challenges such as weak high-end demand and rising inventory pressure [1] Group 2 - The sales landscape is evolving, with traditional sales channels remaining dominant while new formats like e-commerce live streaming are increasingly penetrating the market [1] - Provincial and municipal price monitoring agencies will continue to track seafood market dynamics and enhance data analysis to support market supply and price stability [2]

Investment Rating - The report maintains a positive outlook on the Hong Kong pharmaceutical industry, particularly on innovative drugs, indicating that the sector has entered a profitability phase [1]. Core Insights - The report highlights that the total revenue of 149 Hong Kong-listed pharmaceutical companies reached CNY 896.12 billion in the first half of 2025, reflecting a 1% increase, while net profit attributable to shareholders was CNY 61.99 billion, up 29.7% [3][11]. - The innovative drug sector has shown significant growth, with 36 companies reporting a revenue of CNY 28.5 billion, a 15.8% increase, and a net profit of CNY 1.8 billion, marking a turnaround to profitability [4][12]. - The report emphasizes the importance of differentiated products and strong commercialization capabilities for companies in the innovative drug sector, suggesting that these factors will drive future growth [3][4]. Summary by Sections Overall Performance - The total revenue for the Hong Kong pharmaceutical industry in H1 2025 was CNY 896.12 billion, with a net profit of CNY 61.99 billion, indicating a positive trend in profitability [3][11]. - 57% of the companies reported positive net profit growth, while 50% achieved revenue growth [11][6]. Sector Breakdown - **Innovative Drugs**: Revenue of CNY 28.5 billion (+15.8%), net profit of CNY 1.8 billion, indicating a shift to profitability [4][12]. - **Chemical Preparations**: Revenue of CNY 90.8 billion (-7.1%), net profit of CNY 20.8 billion (+52.9%), suggesting a potential industry turning point [4][5]. - **Medical Devices**: Revenue of CNY 22.2 billion (+3.5%), net profit of CNY 1.9 billion, with varied trends across sub-sectors [4][5]. - **CXO**: Revenue of CNY 49.8 billion (+11.2%), net profit of CNY 12.8 billion (+93.7%), showing strong growth [4][5]. - **Traditional Chinese Medicine**: Revenue of CNY 58.5 billion (-1.8%), net profit of CNY 4.3 billion (-11.5%), indicating challenges in the sector [5][6]. R&D and Expenses - R&D expenses totaled CNY 31.4 billion, down 7.8%, with a decreasing trend in R&D expense ratios [16][24]. - Sales expenses reached CNY 77.7 billion, down 1.5%, and management expenses were CNY 58.7 billion, down 7.3% [16][24]. 18A Companies Performance - The report analyzed 50 Hong Kong 18A pharmaceutical companies, which generated CNY 44.9 billion in revenue, a 31.48% increase, and a net profit of CNY 2.727 billion, marking a significant turnaround with a 128.4% growth [29][34]. - Cash and cash equivalents for these companies reached CNY 84.4 billion, up 26.99% year-on-year [34][35]. International Expansion - The report notes that the international recognition of domestic innovative drugs is increasing, with over 20 licensing out projects totaling over USD 2 billion, indicating a growing trend in global market engagement [35][36].

Group 1 - The South Korean government has decided to implement a visa-free entry policy for Chinese group tourists from September 29 this year to June 30 next year, which is expected to positively impact the domestic tourism and circulation industry [1] - In the first half of this year, South Korea received 2.527 million Chinese tourists, a year-on-year increase of 13.9%, recovering to 90% of the level seen in the same period of 2019 before the pandemic [1] - The industry anticipates that the new visa-free policy, launching just before China's "Golden Week" holiday, could lead to a significant boost in the autumn tourism market [1] Group 2 - The hotel industry is actively launching customized travel products for Chinese tourists and conducting various marketing activities to create a welcoming atmosphere in advance [1] - The duty-free industry believes that group tourists generally have a higher per capita spending level compared to independent travelers, and the visa-free measures are expected to inject positive momentum into sales recovery [1]

Core Insights - The Chinese pharmaceutical industry possesses advantages in population and domestic demand, manufacturing and supply chain, and rapidly improving innovation capabilities, while the number of Chinese assets going abroad continues to rise [1][2] - In the face of external challenges, the industry needs to focus on domestic stability and external expansion, emphasizing supply chain autonomy, innovation, and integration domestically, while accelerating internationalization to seize global opportunities [1][2] Domestic Focus - Policy outlook indicates that reforms are entering a deep-water zone, with high-quality growth becoming the norm; key areas of focus include optimization of drug and consumable procurement policies, diversified payment methods, and medical service price reforms by the second half of 2025 [3] - The pharmaceutical supply chain is undergoing optimization and active innovation transformation, with a focus on supply chain security [3] - There are positive prospects for import substitution and merger integration opportunities in medical devices, with attention to new technology directions such as AI and brain-machine interfaces [3] - The industry is observing a recovery rhythm and long-term transformation in traditional Chinese medicine, pharmacies, distribution, medical services, and vaccines [3] External Expansion - Chinese innovations in pharmaceuticals are gaining recognition on the international stage, with ongoing strengthening of industry trends [4] - The pharmaceutical upstream and life sciences sectors are actively exploring overseas markets to seek a second growth curve [4] - Short-term tariff disruptions in raw materials are limited, with a focus on industry transformation opportunities [4] - The trend of internationalization in medical devices is firmly supported, with attention to opportunities for independent sales and business development of certain innovative devices [4] - The introduction of immunoglobulin provides opportunities for blood products to go abroad, with ongoing progress in overseas registration [4] - The export of vaccines is becoming more diversified, with an expected acceleration in progress [4] Investment Outlook for Second Half of 2025 - The focus on innovation will center around innovative drugs and pharmaceutical companies (e.g., bispecific antibodies, T-cell engagers, nuclear medicine) and medical devices (e.g., AI, brain-machine interfaces) [5] - The export focus will highlight representative segments such as innovative drugs and medical device companies [5] - Marginal changes will be driven by policy improvements (including pharmaceutical distribution and medical equipment updates) and supply-demand relationship improvements in sectors like CXO, life sciences, and upstream biopharmaceuticals [5] - The integration focus will recommend attention to medical devices and traditional Chinese medicine sub-sectors, certain pharmaceutical companies, and state-owned enterprises [5]